Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.68 USD

201.68
5,108,724

+1.21 (0.60%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $200.01 -1.67 (-0.83%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (88 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

This is Why AbbVie (ABBV) is a Great Dividend Stock

by Zacks Equity Research

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does AbbVie (ABBV) have what it takes? Let's find out.

Merck's Chronic Cough Candidate Achieves Goals in Phase III

by Zacks Equity Research

Merck's (MRK) two phase III studies on gefapixant (MK-7264) for the treatment of refractory or unexplained chronic cough meet the primary efficacy endpoints.

Johnson & Johnson (JNJ) Catches Eye: Stock Jumps 7.4%

by Zacks Equity Research

Johnson & Johnson (JNJ) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

Improve Your Retirement Income with These 3 Top-Ranked Dividend Stocks - March 18, 2020

by Zacks Equity Research

The traditional approaches to retirement planning are longer covering all expenses in nest egg years. So what can retirees do? Thankfully, there are alternative investments that provide steady, higher-rate income streams to replace dwindling bond yields.

Know These 3 Facts to Avoid Paying Half Your Retirement Income to the IRS - March 18, 2020

by Zacks Equity Research

Like the majority of investors, you're most likely working on a retirement portfolio that will provide a large enough nest egg to give you a comfortable retirement. Make sure you know all about what financial planners call the accumulation and distribution phases of retirement planning.

AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

In the latest trading session, AbbVie (ABBV) closed at $72.99, marking a -1.72% move from the previous day.

How Trading Your Own Retirement Can Fleece Your Financial Future - March 17, 2020

by Zacks Equity Research

From understanding your risk tolerance to maintaining emotional control, achieving your retirement goals takes a much different investing approach than regular stock trading.

AbbVie (ABBV) Jumps: Stock Rises 8.6%

by Zacks Equity Research

AbbVie (ABBV) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Simple Secrets Anyone Can Use to Reach Early Retirement - March 16, 2020

by Zacks Equity Research

Achieving the financial freedom to retire early is a dream for most, but making that dream a reality isn't as tricky as it sounds. If you are willing to make some serious lifestyle changes and sacrifices, it can be possible.

J&J Signs Another Collaboration to Develop Coronavirus Vaccine

by Zacks Equity Research

J&J (JNJ) is actively pursuing its development plans related to coronavirus vaccine. The company is partnering with several public/private organizations to accelerate its vaccine development.

Kinjel Shah headshot

Pharma Stock Roundup: ABBV, LLY Coronavirus Product Development Efforts, FDA Updates

by Kinjel Shah

Lilly (LLY) signs deal with AbCellera to co-develop antibody therapies to treat COVID-19. AbbVie (ABBV) supports studies evaluating Kaletra for treating COVID-19.

Weekly Biotech Update After WHO Declares Coronavirus a Pandemic

by Zacks Equity Research

Several pharma/companies are working to develop a treatment for novel coronavirus as WHO declares Covid-19 a pandemic.

Roche's (RHHBY) Coronavirus Test Achieves EUA From the FDA

by Zacks Equity Research

Roche's (RHHBY) cobas SARS-CoV-2 Test for the qualitative detection of SARS-CoV-2, the virus that causes the COVID-19 disease, gets EUA from the FDA.

Ekta Bagri headshot

Biotech Sector in Focus as Coronavirus Spreads Panic

by Ekta Bagri

The outbreak of COVID-19 has brought the volatile biotech sector under the spotlight as both large and small companies rush to develop treatments and vaccines to combat this pandemic.

Gilead (GILD) Announces Positive Long-Term Results on Descovy

by Zacks Equity Research

Gilead (GILD) announces long-term results from the DISCOVER study, which showed that Descovy is effective for HIV prevention with non-inferior efficacy to Truvada.

AbbVie Backs Studies on HIV Drug Kaletra for Coronavirus Cure

by Zacks Equity Research

AbbVie (ABBV) donates Kaletra/Aluvia to the government of China for experimental use in coronavirus treatment

Bristol-Myers Empliciti Combo Fails in First-Line Myeloma Study

by Zacks Equity Research

Bristol-Myers' (BMY) Empliciti, Revlimid and dexamethasone combination regimen fails to improve progression free survival in first-line multiple myeloma patients.

The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Apple, Facebook, AbbVie, Illumina and Freeport-McMoRan

Is Amgen (AMGN) Truly One of the Best Biotech Stocks to Own?

by Zacks Equity Research

Amgen (AMGN) boasts a strong biosimilars portfolio, which can drive long-term growth. Amgen is also progressing with its pipeline while regularly pursuing business development deals.

Mark Vickery headshot

Top Research Reports for Apple, Facebook & AbbVie

by Mark Vickery

Today's Research Daily features new research reports on 12 major stocks, including Apple (AAPL), Facebook (FB) and AbbVie (ABBV).

AbbVie (ABBV) Up 1.9% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

AbbVie (ABBV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Allergan's (AGN) Glaucoma Implant Durysta Gets FDA Approval

by Zacks Equity Research

Allergan's (AGN) Durysta (bimatoprost) gets FDA approval to reduce intraocular pressure in patients with open-angle glaucoma.

Can-Fite (CANF) to Explore RA Drug for Coronavirus Treatment

by Zacks Equity Research

Can-Fite (CANF) announces plans to explore piclidenoson for the treatment of coronavirus.

Kinjel Shah headshot

Pharma Stock Roundup: Trump, Pharma Executives Meeting on Coronavirus, FDA Updates

by Kinjel Shah

Trump asks pharma firms to accelerate development of coronavirus vaccine/treatment. FDA approves Sanofi's (SNY) Sarclisa and Allergan'sa (AGN) Durysta.

The Truth About Market Timing - March 06, 2020

by Zacks Equity Research

Is the ability to time the markets more of a data-driven science or a 'gut - feeling' art?